(222) Analgesic efficacy of tapentadol immediate release in patients with pain from end stage joint disease

Abstract

Tapentadol is a novel, centrally acting analgesic in a single molecule with a dual mode of action: mu-opioid receptor agonism and norepinephrine reuptake inhibition. The efficacy of tapentadol immediate release (IR) was studied in a double-blind, randomized, placebo-controlled, multicenter trial of candidates for primary joint replacement surgery for end-stage joint disease. A total of 659 patients, randomly assigned 1:1:1:1, received an oral dose of placebo, tapentadol IR 50 or 75 mg, or oxycodone IR 10 mg every 4 to 6 hours (max 6 doses/day) and were included in the efficacy analyses.